🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

84 results for “Alnylam Netherlands B.V.” Clear

  1. 0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran

    Alnylam Netherlands B.V.

    High cardiovascular risk, Established cardiovascular disease, Hypertension

    phase 3 small molecule active

    1 trial

  2. 0.9% Sodium chloride, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  3. ALN-TTRSC04, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Hereditary transthyretin-mediated amyloidosis with polyneuropathy

    phase 3 small molecule active

    1 trial

  4. Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  5. Amvuttra 25 mg solution for injection in pre-filled syringe, Onpattro 2 mg/mL concentrate for solution for infusion.

    Alnylam Netherlands B.V.

    Hereditary Transthyretin Amyloidosis

    phase 3 small molecule active

    1 trial

  6. Givosiran

    Alnylam Netherlands B.V.

    Acute Hepatic Porphyria

    phase 3 small molecule completed

    1 trial

  7. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1

    phase 3 small molecule completed

    1 trial

  8. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria

    phase 3 small molecule completed

    1 trial

  9. Nucresiran

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis With Cardiomyopathy

    phase 3 small molecule active

    1 trial

  10. Nucresiran

    Alnylam Netherlands B.V.

    Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

    phase 3 small molecule active

    1 trial

  11. Onpattro 2 mg/mL concentrate for solution for infusion., Sodium Chloride Intravenous Infusion BP 0.9% w/v

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  12. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis

    phase 3 small molecule completed

    1 trial

  13. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis, Familial

    phase 3 small molecule completed

    1 trial

  14. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis, Hereditary

    phase 3 small molecule completed

    1 trial

  15. Placebo

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  16. Placebo

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1 (PH1)

    phase 3 small molecule completed

    1 trial

  17. Placebo for Nucresiran, ALN-TTRSC04

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  18. Revusiran (ALN-TTRSC)

    Alnylam Netherlands B.V.

    Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

    phase 3 small molecule completed

    1 trial

  19. Vutrisiran

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 small molecule active

    2 trials

  20. Zilebesiran

    Alnylam Netherlands B.V.

    High Risk Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  21. patisiran (ALN-TTR02)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 3 small molecule completed

    1 trial

  22. ALN-2232

    Alnylam Netherlands B.V.

    Obesity

    phase 2 small molecule active

    1 trial

  23. ALN-4324

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  24. ALN-4324

    Alnylam Netherlands B.V.

    Obese or Overweight Healthy Volunteers

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources